4 reports

ORAL HDV-INSULIN USES A UNIQUE, BIONANOTECHNOLOGY BASED CELL TARGETING SYSTEM TO PREFERENTIALLY DELIVER INSULIN TO SPECIFIC SITES IN THE BODY.

  • Immunotherapy
  • Surgery
  • United States
  • Company
  • Product Initiative
  • TRETINOIN - DRUG PROFILE

Rituximab was given on day ## of cycles ##-## (Arm A), while obinutuzumab was given on days ##, ## and ## of cycle ## and day ## of cycles ##-## (Arm B).

  • Cancer
  • Immunotherapy
  • Surgery
  • United States
  • Merck & Co., Inc.

Group ## (G##) received ofatumumab on Day ## of Cycle ##, and Imbruvica on Day ## of Cycle ##.

  • Cancer
  • Immunotherapy
  • Surgery
  • United States
  • Product Initiative
  • 3.7 PATENT TRENDS

New area of research called nanobiotechnology has also emerged.

  • Surgery
  • World
  • Market Size
  • DePuy Synthes, Inc.
  • DJO